BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Deng W, Chen X, Jiang K, Song X, Huang M, Tu ZC, Zhang Z, Lin X, Ortega R, Patterson AV, Smaill JB, Ding K, Chen S, Chen Y, Lu X. Investigation of Covalent Warheads in the Design of 2-Aminopyrimidine-based FGFR4 Inhibitors. ACS Med Chem Lett 2021;12:647-52. [PMID: 33859803 DOI: 10.1021/acsmedchemlett.1c00052] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Nam Y, Shin I, Kim Y, Ryu S, Kim N, Ju E, Sim T. Anti-cancer effects of 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one derivatives on hepatocellular carcinoma harboring FGFR4 activation. Neoplasia 2022;24:34-49. [PMID: 34864570 DOI: 10.1016/j.neo.2021.11.011] [Reference Citation Analysis]
2 Chen X, Li H, Lin Q, Dai S, Yue S, Qu L, Li M, Guo M, Wei H, Li J, Jiang L, Xu G, Chen Y. Structure-based design of a dual-warhead covalent inhibitor of FGFR4. Commun Chem 2022;5. [DOI: 10.1038/s42004-022-00657-9] [Reference Citation Analysis]